VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Anti-TIM-3 antibody MBG453 + hypomethylating agents for high-risk MDS & AML

Uma Borate, MD, Oregon Health & Science University, Portland, OR, discusses the use of MBG453, a monoclonal anti-TIM-3 antibody in combination with hypomethylating agents for high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients in a Phase Ib clinical trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter